Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Eye injection burden varies by disease, study finds

NCT ID NCT07514559

Knowledge-focused Sponsor: Hospital Hietzing Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at how much of a burden patients feel from repeated anti-VEGF eye injections for three different eye diseases: wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema. Researchers surveyed 393 patients about their treatment burden, socioeconomic status, and demographics. The goal was to identify factors that might affect whether patients stick with their treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
anti-VEGF (vascular endothelial growth factor) injections
What this could lead to
If successful, this could help doctors understand which patient groups struggle most with treatment burden, leading to better support and adherence.
What could go wrong
This is an observational study that measures patient perceptions, not a treatment trial. It cannot prove that changing anything will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

393 people

The number who actually took part.

Started

May 2023

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

393 patients (305 with nAMD, 55 with CME and 33 with DME)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * undergone a minimum of 5 IVT's and had visited the retina clinic for at least 6 months Exclusion Criteria: * eye surgery in the preceding six months * notable cognitive impairment, such as dementia * age \<18 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age related macular degeneration (ARMD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

age-related macular degeneration central retinal vein occlusion with macular edema diabetic macular edema macular degeneration retinal vein occlusion wet macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Age related macular degeneration (ARMD) Diabetic macular edema (DME) Retinal vein occlusion (RVO)

Contacts and locations

Locations

  • Hietzing Hospital

    Vienna, 1130, Austria

More trials for these conditions

Other studies related to the condition(s) this trial covers.